InvestorsHub Logo

tradero

06/05/19 1:17 PM

#6539 RE: 236T568 #6538

Woww! That is a huge statement and I have not read much reasoning behind it.

I do not think there is any problem with the stem cells ISCO is working with because they are of different kind than those the newspaper you mentioned was talking about.

The big problem with ISCO (and it has always been so) is that the revenues obtained from other ISCO activities can not cover the cost of the trials. Thus the dilution issue